Exchange: NASDAQ·Updated 07:30 PM EDT

PRTA News

News
all
press releases
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Zacks
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Zacks
More News
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright...
Business Wire
KMDA or PRTA: Which Is the Better Value Stock Right Now?
KMDA vs. PRTA: Which Stock Is the Better Value Option?
Zacks
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
Zacks
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and first six months of 2026 and provided business highlights...
Business Wire
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Prothena to Report Second Quarter 2026 Financial Results on August 6
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2026 financial results on Thursday...
Business Wire
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?
Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.
Zacks
SRPT or PRTA: Which Is the Better Value Stock Right Now?
SRPT vs. PRTA: Which Stock Is the Better Value Option?
Zacks

Advertisement|Remove ads.